Rahman Mahbubur, Sekimoto Miho, Hira Kenji, Koyama Hiroshi, Imanaka Yuichi, Fukui Tsuguya
Department of General Medicine and Clinical Epidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Prev Med. 2002 Jul;35(1):70-7. doi: 10.1006/pmed.2002.1043.
Bacillus Calmette-Guerin (BCG) revaccination has been implemented in Japan among tuberculin-negative first grade primary and first grade junior high school students for decades. Controversies regarding the effectiveness of BCG revaccination and low incidence of tuberculosis (TB) among Japanese children prompted this study.
Cost-effectiveness and cost-benefit analyses were conducted for a cohort of schoolchildren who underwent revaccination during 1996. The study population was a hypothetical cohort comprising 1.35 million first grade primary school and 1.51 million first grade junior high school students enrolled in 1996 at locations throughout Japan. Assuming 50% vaccine efficacy for revaccination, a 10-year duration of protection, and 5% annual discount rate, we calculated the total hypothetical number of TB cases averted, the cost and number of immunizations per TB case averted, and the benefit-cost ratio for the program.
The revaccination program for 1996 schoolchildren cohort would prevent 296 TB cases over a 10-year period at a cost of US$ 108,378 per case averted. About 4,963 immunizations would be required to prevent one child from developing TB. The benefit-cost ratio remained at 0.13 with baseline assumptions and ranged from 0.05 to 0.29 and from 0.02 to 0.74 for one-way and two-way sensitivity analyses, respectively.
BCG revaccination among schoolchildren is not supported by available scientific and economic data. Based on the results of this study, current BCG revaccination policies in Japan and other countries should be reexamined.
卡介苗复种在日本已在结核菌素阴性的小学一年级和初中一年级学生中实施了数十年。关于卡介苗复种的有效性以及日本儿童结核病发病率低的争议促使了这项研究。
对1996年接受复种的一组学童进行了成本效益和成本效益分析。研究人群是一个假设队列,包括1996年在日本各地入学的135万小学一年级学生和151万初中一年级学生。假设复种疫苗效力为50%,保护期为10年,年贴现率为5%,我们计算了避免的结核病病例的总假设数、避免每例结核病病例的成本和免疫接种次数,以及该项目的效益成本比。
1996年学童队列的复种计划在10年内可预防296例结核病病例,每避免一例病例的成本为108,378美元。大约需要4,963次免疫接种才能防止一名儿童患结核病。在基线假设下,效益成本比保持在0.13,单向和双向敏感性分析的效益成本比分别在0.05至0.29和0.02至0.74之间。
现有科学和经济数据不支持对学童进行卡介苗复种。根据这项研究的结果,日本和其他国家目前的卡介苗复种政策应重新审视。